Page 9 - Intercept Pharmaceutical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dive Brief: The Food and Drug Administration on Wednesday restricted the use of Intercept Pharmaceuticals' liver disease drug Ocaliva after an investigation linked it to severe injuries including liver failure in certain patients. In most cases, the benefits of Ocaliva outweigh the risks for patients with primary biliary cholangitis, the FDA said. But the agency announced Wednesday that doctors should not prescribe the medicine for patients with advanced cirrhosis, or permanent scarring. The new contraindication follows a safety warning added in 2018 to caution physicians about overdosing pat...

Author Bio A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and investment planning. You'll often find him writing about Obamacare, marijuana, drug and device development, Social Security, taxes, retirement issues and general macroeconomic topics of interest. Follow @TMFUltraLong If there's been a pretty consistent theme over the past decade, it's that growth stocks reign supreme. With lending rates hovering at or near historic lows, high-growth businesses have had the ability to borrow at cheap rat...

Author Bio Rich has been a Fool since 1998 and writing for the site since 2004. After 20 years of patrolling the mean streets of suburbia, he hung up his badge and gun to take up a pen full time. Having made the streets safe for Truth, Justice, and Krispy Kreme donuts, he now patrols the markets looking for companies he can lock up as long-term holdings in a portfolio. His coverage reflects his passion for motorcycles, booze, and guns (though typically not all exercised at the same time), but his writing also covers the broader sectors of consumer goods, technology, an...